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NEOPLASIA
Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays
define a leukemic subgroup of disease and predict patient outcome
Fanny Rubio-Moscardo, Joan Climent, Reiner Siebert, Miguel A. Piris, Jose I. Martı´n-Subero, Inga Niela¨nder, Javier Garcia-Conde,
Martin J. S. Dyer, Maria Jose Terol, Daniel Pinkel, and Jose A. Martinez-Climent
To identify recurrent genomic changes in
mantle cell lymphoma (MCL), we used
high-resolution comparative genomic hy-
bridization (CGH) to bacterial artificial
chromosome (BAC) microarrays in 68 pa-
tients and 9 MCL-derived cell lines. Array
CGH defined an MCL genomic signature
distinct from other B-cell lymphomas, in-
cluding deletions of 1p21 and 11q22.3-
ATM gene with coincident 10p12-BMI1
gene amplification and 10p14 deletion,
along with a previously unidentified loss
within 9q21-q22. Specific genomic alter-
ations were associated with different sub-
groups of disease. Notably, 11 patients
with leukemic MCL showed a different
genomic profile than nodal cases, includ-
ing 8p21.3 deletion at tumor necrosis
factor–related apoptosis-inducing ligand
(TRAIL) receptor gene cluster (55% ver-
sus 19%; P  .01) and gain of 8q24.1 at
MYC locus (46% versus 14%; P  .015).
Additionally, leukemic MCL exhibited fre-
quent IGVH mutation (64% versus 21%;
P  .009) with preferential VH4-39 use
(36% versus 4%; P  .005) and followed a
more indolent clinical course. Blastoid
variants, increased number of genomic
gains, and deletions of P16/INK4a and
TP53 genes correlated with poorer out-
comes, while 1p21 loss was associated
with prolonged survival (P  .02). In mul-
tivariate analysis, deletion of 9q21-q22
was the strongest predictor for inferior
survival (hazard ratio [HR], 6; confidence
interval [CI], 2.3 to 15.7). Our study high-
lights the genomic profile as a predictor
for clinical outcome and suggests that
“genome scanning” of chromosomes
1p21, 9q21-q22, 9p21.3-P16/INK4a, and
17p13.1-TP53 may be clinically useful in
MCL. (Blood. 2005;105:4445-4454)
© 2005 by The American Society of Hematology
Introduction
Mantle-cell lymphoma (MCL) is a distinct subtype of B-cell
non-Hodgkin lymphoma (B-NHL) characterized by the translo-
cation t(11;14)(q13;q32) that leads to overexpression of cyclin
D1.1,2 However, experimental evidence indicates that cyclin D1
activation may not be sufficient to induce malignant transforma-
tion, requiring concurrent deregulated expression of other
dominant oncogenes and loss of tumor suppressor gene func-
tions for lymphoma development.3 The portrait of genomic
aberrations in addition to t(11;14)(q13;q32) has been exten-
sively characterized using conventional cytogenetic and compara-
tive genomic hybridization (CGH) methods.4-9 More recently,
matrix CGH to dedicated DNA microarrays with 812 selected
bacterial artificial chromosome (BAC) or P1-artificial chromo-
some (PAC) clones has described a typical pattern of genomic
imbalances in MCL, revealing a higher number of aberrations
than in previous CGH studies.10 Two additional reports have
used CGH to BAC microarrays to delineate with high accuracy
previously known as well as novel regions of DNA copy number
increase and decrease in MCL genomes.11,12 It is remarkable that
MCL shares several genomic gains and losses with other B-cell
malignancies.4-10,13,14 However, the comparative high-resolution
genomic analysis between MCL and other B-NHL subtypes has
not yet been addressed. The repertoire of genomic imbalances is
correlated with the lymphoma phenotype and survival in
patients with MCL. The most typical examples are the deletions
of TP53 and P16/INK4a genes, both associated with aggressive
MCL.15-18 Using CGH, Bea et al reported that blastoid variants
show an increased number of changes with respect to tumors
with typical pathologic appearance.5 In another report, trisomies
of 3q and 8q were observed in MCL with unmutated IGVH genes
whereas trisomy of 12q was more common in cases with
mutated phenotype.19 In our previous CGH study, patients with
leukemic MCL presented typically the deletion of chromosome
8p.7 The 8p loss was subsequently classified as a common
change in MCL,8,10,19,20 but the association with leukemic
disease was not clarified. More recently, Orchard et al21 reported
that a subset of MCL displays mutated IGVH genes and includes
patients with good prognosis and nonnodal leukemic disease.
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The definition of genetic differences among patients with MCL
with diverse clinical features and outcomes should improve
lymphoma classification, help in outcome prediction, and facili-
tate selection of treatment.
In the present study, we determined the pattern of genomic
imbalances in a series of 68 patients with MCL and 45 B-cell
lymphoma cell lines using CGH to a microarray with about 2400
BAC and PAC clones over the genome.22 Our study provides an
example on how genome scanning of tumor cells using array-based
CGH methods may be clinically useful in MCL as well as may
implicate novel oncogene and suppressor gene loci in the pathogen-
esis of this lymphoma.
Patients, materials, and methods
Subjects of study
This is a retrospective study. We included samples obtained from 68
patients newly diagnosed with MCL. These comprised 58 cases from a
previously published series23 as well as 10 additional cases. All tumors
fulfilled World Health Organization (WHO) diagnostic criteria for MCL,
including the demonstration of cyclin D1 overexpression, the t(11;14)(q13;
q32) cytogenetically, and/or CCND1-IGH gene rearrangement by fluores-
cence in situ hybridization (FISH) or polymerase chain reaction (PCR).2
Genomic DNA was extracted from frozen tissue blocks (44 cases), bone
marrow (BM) (6 cases), and peripheral blood (PB) (18 cases). Rearranged
IGVH genes were amplified using a seminested PCR method, as described
previously.23 Clinical features of the patients are summarized in Table 1.
Fifty-seven cases had lymph node involvement at diagnosis, whereas 11
cases were classified as nonnodal leukemic MCL on the basis of the absence
at diagnosis of lymph node enlargement according to physical examination
and computed tomography (CT) scan. Patients were treated with different
chemotherapy schemes (58 cases), splenectomy (3 cases), and gastrointesti-
nal resection (1 case), whereas 5 patients received no therapy; in 1 case, no
clinical information was available. Complete remission was achieved in 22
cases, whereas 15 had partial response. This study was approved by the
institutional review board of the Hospital Clinico University of Valencia.
Patients were provided with informed consent, per Declaration of Helsinki.
Cell lines
A panel of 45 cell lines (9 MCL derived and 36 derived from patients
comprising most other subtypes of B-cell malignancies) were studied:
Granta 519, HBL-2, SP-49, Z-138, REC-1, NCEB-1, JVM-2, UPN-1, and
UPN-2 (MCL); OZ, VAL, Karpas 422, DOHH-2, Karpas 353, PR-1,
OCI-LY8, Karpas 231, SU-DHL6, ROS-50, RL, SCI-1, and Granta 452
(diffuse large B-cell lymphoma with t(14;18)(q32;q21)); BEVA, CTB-1,
MD-901, MD-903, RIVA, RCK-8, and CIPULLO (diffuse large B-cell
lymphoma lacking t(14;18)); ELIJAH, NAB-2, PL-29018, SERAPHINA,
Wien-133, P-32, BALM-9, BL-41, CA-46, Namalwa, and KHM-10B
(Burkitt lymphoma); SSK-41 and Karpas 1718 (marginal zone lymphoma);
Karpas 1106 (primary mediastinal B-cell lymphoma); JVM-13 (B-cell
prolymphocytic leukemia); and GASH (hairy cell leukemia). References
for the derivation of the cell lines are summarized on Supplemental Table
S1 (at the Blood website, see the Supplemental Tables link at the top of the
online article).
Microarray-based comparative genomic hybridization
(array CGH)
Genome-wide analysis of DNA copy number changes of 113 samples (68
patients and 45 cell lines) was performed using array CGH on a microchip
with about 2460 BAC and P1 clones in triplicate University of California
San Francisco ([UCSF] Hum Array 2.0) with a resolution of 1.4 Mb across
the genome.22 Methods and analytic procedures have been described
elsewhere in detail.24,25 Briefly, 0.2 g test (tumor) and reference genomic
DNAs were labeled by random priming using cyanine 3 (Cy3) and Cy5,
respectively. After 48 hours of hybridization, slides were washed and
mounted with DAPI (4,6 diamidino-2-phenylindole). The images of the
arrays were captured using a charge-coupled device (CCD) camera, and the
Table 1. Clinical description of 68 patients with MCL: comparison of nodal versus nonnodal leukemic MCL
Patients with MCL Nodal group Leukemic group P
Patients
No. 68 57 11 NA
Male; female 49; 19 42; 15 7; 4 NS
Median age, y (range) 70 (46-86) 69 (46-86) 74 (49-77) NS
Clinical features
PB disease (%) 28 (41) 17 (30) 11 (100)  .001
BM infiltration (%) 40 (60) 29 (52) 11 (100) .002
Splenomegaly (%) 29 (43) 25 (45) 4 (36) NS
Waldeyer ring (%) 5 (7) 5 (9) 0 (0) NS
GI tract (%) 9 (13) 9 (16) 0 (0) NS
IPI 4 to 5 (%) 8 (12) 8 (14) 0 (0) NS
IgVH mutation (%) 19 (28) 12 (21) 7 (64) .009
IgVH family
VH3-23 (%) 5 (7) 4 (7) 1 (9) NS
VH3-21 (%) 7 (10) 7 (13) 0 (0) NS
VH3-34 (%) 9 (13) 8 (14) 1 (9) NS
VH3-59 (%) 8 (12) 6 (11) 2 (18) NS
VH4-39 (%) 6 (9) 2 (4) 4 (36) .005
Cytology
Blastoid (%) 11 (16) 11 (20) 0 (0) NS
Classic (%) 57 (84) 46 (81) 11 (100) NA
IPI 4 to 5 (%) 8 (12) 8 (14) 0 (0) NS
Median survival, mo 39 18 42 NA
Survival more than 36 mo (%) 22 (33) 15 (27) 7 (64) .02
Genomic imbalances
del(8)(p21.3) (%) 17 (25) 11 (19) 6 (55) .01
gain 8q24-MYC (%) 13 (19) 8 (14) 5 (46) .015
GI indicates gastrointestinal; IPI, International Prognostic Index; NS, not significant; NA, not applicable.
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“UCSF SPOT” software was used to analyze the images. A second
program, “SPROC,” was used to associate clones with each spot and a
mapping information file that allows the data to be plotted relative to the
position of the BACs on the draft human genome sequence (http://genome.
cse.ucsc.edu/cgi-bin/hgGateway?cladevertebrate&orgHuman&db
hg16&hgsid39217703; July 2003 freeze). A formal data filtering proce-
dure was then performed, and a SPROC output file consisting of averaged
ratios of the triplicate spots for each clone, standard deviations of the
replicates, and plotting positions for each clone on the array was obtained.
For visualization of genomic data, the TreeView program 1.60 (Stanford,
CA) was used. The complete genomic data set from patients and cell
lines with MCL is available in Supplemental Table S2.
Data analysis
Mean log2 ratios (tumoral DNA versus control DNA) were plotted, and the
resultant graphs were converted to the log2 domain. The observed log2
ratios were excluded from further analysis if there were fewer than 2
replicate spots (out of 3) or if the standard deviation of the replicates was
above 0.02. The clones that were present in less than 50% of the samples
were also removed from the dataset. The following mean log2 ratios
(tumoral DNA versus control DNA) were used to classify genomic
aberrations: genomic gain (between 0.39 and 0.95), genomic amplification
(more than 0.95), or genomic loss (lower than  0.5 for hemizygosity and
lower than 1.4 for homozygous deletion).
Statistically significant correlations between the genomic imbalances
and clinical-pathological parameters were analyzed using the Fisher exact
test for categorical parameters and the Mann-Whitney U test for continuous
parameters. Because of the large number of clinical and biologic variables
analyzed in relation to genomic changes, the significance of these associa-
tions was assessed using the false discovery rate test (FDRalgo; http://
www.math.tau.ac.il/roee/meth.htm).26 Overall survival (OS) for each
variable was calculated according to the Kaplan-Meier survival curves and
P values with the log-rank test. Multivariate analysis using the Cox
regression model was performed only with the variables with a P value less
than .05 in the univariate analyses; only one BAC for each abnormal region
was included for the multivariate analysis. Finally, to evaluate the possible
relationship between OS and the total number of genomic gains and losses,
we used the Cox proportional hazard model. The analyses were carried out
using SPSS software for Windows. For delineation of common region of
genomic imbalance in the lymphoma genomes, the position of the
BACs/PACs on the draft human genome sequence according to the May
2004 freeze was used (http://genome.cse.ucsc.edu/cgi-bin/hgGateway?
cladevertebrate&orgHuman&dbhg17&hgsid39217703).
Fluorescence in situ hybridization (FISH) analysis
To confirm the array CGH results, FISH analysis using individual probes
was performed on fixed cells from selected cell line strains and patient
specimens using reported methods.7 The gene loci examined corresponded
to overrepresented regions (CCND1, BCL2, MYC, and BCL6) and deleted
segments (P16-INK4a, TP53, and ATM genes and the 13q14-D13S19
locus). In addition, BACs RP11-89M8, RP11-204M16, and RP11-110I16
(8p21.3 at TRAIL-DR5 locus); RP11-165N12, RP11-100A3, and RP11-
86C3 (13q31.3); RP11-155A5, RP11-111D18, RP11-513O11, RP11-
671P4, RP11-357N12, RP11-97N5, and RP5-1014O16 (at the Xq27-q28
amplicon); RP11-625P19 and RP11-938A5 (which flank the BMI1 locus);
RP11-265K5 and RP11-675F6 (8p11.2 at FGFR1 locus); and recently
described probes for the JAK2 locus at 9p24 were also used for FISH
studies.27 These clones were purchased from Research Genetics (Hunts-
ville, AL), Vysis (Downers Grove, IL), or German Resource Center (Berlin,
Germany).
Multicolor FICTION
Combined immunophenotyping and interphase FISH was applied in case
MCL114 in a multicolor fashion (multicolor FICTION [fluorescence
immunophenotyping and interphase cytogenetics as a tool for the investiga-
tion of neoplasms] technique) following the reported protocol28 for the
simultaneous detection of CCND1 (11q13) chromosomal breakpoints,
BMI1 (10p12, clone RP11-938A5) amplification, and expression of prolif-
eration marker Ki-67. Clones flanking the CCND1 locus (RP11-378E8/RP11-
211G23 and RP11-300I6/RP11-626H12) were labeled with Spectrum
Orange (Vysis) and diethyl aminomethyl coumarin (DEAC), respectively.
Clone RP11-938A5 was labeled with Spectrum Green (Vysis), and the
primary antibody to Ki-67 (clone MIB-1; Dako Cytomation, Hamburg,
Germany) was detected with a secondary antibody with Alexa-594 (Molecu-
lar Probes, Leiden, The Netherlands).
Results
Genome scanning of lymphoma genomes with high-resolution
array CGH
To define with high resolution the genomic profile of MCL cells,
we scanned 68 primary MCL samples and 9 derived MCL cell lines
using array CGH with a microchip that includes 2460 BAC and
Figure 1. Array CGH profile of MCL. (A, left) Array CGH
profile of MCL and other B-NHL subtypes. Patients with
MCL are ordered from left to right according to the length
of OS time, ranging from 0 to 115 months. FCL indicates
follicle center lymphoma; BL, Burkitt lymphoma; DLBCL,
diffuse large B-cell lymphoma; MZL, marginal zone lym-
phoma. (Right) Genomic delineation of the deletions of
1p21.2-p21.3 and of 10p14 with amplification of 10p12
(BMI1 gene locus). Genomic gains are shown in red,
genomic losses in green, and regions with normal DNA
copy number in black. (B) Multicolor FICTION analysis of
case no. MCL114. BMI1 amplification was more common
in apparently proliferating cyclin D1–positive MCL cells
(38 of 50 cells; 76%) as adjudged by Ki-67 staining,
whereas those cyclin D1–positive cells negative for Ki-67
showed this gene amplification less commonly (14 of 50
cells; 28%). A Zeiss Axioskop 2 fluorescence microscope
(Zeiss, Gottingen, Germany) equipped with appropriate
filter sets was used.
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PAC clones spanning the genome (Figure 1A). As an initial
comparison, we also profiled 36 cell lines derived from other
B-NHL subtypes. To assess the sensitivity of the technique, the
array CGH patterns were compared with previous conventional
CGH of 22 patients with MCL and 7 MCL cell lines.7 On average,
each of these tumors displayed 8 changes in conventional CGH
(range, 0 to 22), including 4.4 genomic gains and 3.6 losses,
whereas in array CGH analysis the number of altered regions was
14 per tumor (range, 0 to 35), including 7.5 gains and 6.5 losses. On
average, array CGH detected in each sample 8 new genomic
abnormalities that were undetected in conventional analysis and
excluded, on average, 2 false CGH abnormalities, most of which
corresponded to the telomeric chromosome regions. The mean
number of clones that were altered on each patient sample was 159
(7.9% of all efficiently hybridized clones), corresponding to 66
gains (3.3%) and 93 losses (4.6%). In the 9 MCL cell lines, there
was an increased number of abnormal clones with respect to
primary tumors (305 clones; 15.5%), based on the higher number
of gains (221 clones; 11%), but a similar number of losses were
seen (84 clones; 4.5%). The remaining B-NHL cell lines showed
higher number of changes, corresponding to 392 abnormal clones
(18.9%) with 231 gains (11%) and 161 losses (7.9%). To evaluate
reproducibility of array CGH experiments, SCI1, PR1, OCI-Ly8,
and Z138 cell lines and patient no. MCL045 were analyzed twice.
In the comparative analysis, 13 clone pairs from the paired tumors
(0.6%; range, 4%-33%) from the different array CGH experiments
showed discordant values (defined as differences in log2 value
exceeding 0.3). We also used FISH to evaluate specific genomic
alterations in selected tumors: 135 of the 140 FISH experiments
(96.4%) confirmed the DNA copy number changes of array CGH
experiments. The detailed validation array CGH and FISH experi-
ments are shown in Supplemental Table S3. In summary, array
CGH was more sensitive than conventional CGH and was a highly
reproducible method for the scanning of lymphoma genomes.
Delineation of critical regions of recurrent genomic
aberration in MCL
Array CGH analysis identified a typical pattern of genomic
changes in MCL (Figure 2). By overlapping the segments showing
BAC and PAC clone variation in the different samples, we
delineated the minimal regions of common amplification, low-level
gain, and loss as shown in Table 2.
Amplifications and gains. Forty-eight amplification events
(defined as the gain of more than 2 copies of DNA) targeting 25
different loci were identified. Amplification levels ranged from
3-fold to 7-fold. Amplicons included genes previously identified as
being either amplified or overexpressed in MCL: CCND1 at
11q13.3 (observed in 1 MCL primary sample and 2 cell lines),
BCL6 in 3q27.3 (2 primary MCLs), BCL2 in 18q21.3 (3 MCL cell
lines), CDK4 in 12q14.1 (1 MCL cell line), and GPC5 in 13q31.3
(1 MCL primary tumor and 1 cell line) (Figure 3A).1,4,6-8,29,30 One
of the most frequent amplified sites, observed in 8 of 68 (12%)
MCL primary samples and in 1 of 9 (11%) MCL cell lines, was
chromosome band 10p12.2, involving a critical segment that
spanned the BAC clones RP11-200C22 and RP11-75N18. The
recurrent peak of amplification was delineated to clone RP11-
73E18, which contains the BMI1 gene locus.30 To validate the array
CGH data, clones RP11-625P19 and RP11-938A5, which are not
included into the array and flank the BMI1 locus, were shown by
FISH to be both amplified. In one specimen (case no. MCL114),
BMI1 amplification was more common in apparently proliferating
cyclin D1–positive MCL cells (38 of 50 cells; 76%) as adjudged by
Ki-67 staining, whereas those cyclin D1–positive cells negative for
Ki-67 showed this gene amplification less commonly (14 of 50
cells; 28%) (Figure 1B). In contrast with other published reports,
BMI1 amplification was not only observed in cases without
P16-INK4a deletion, as both alterations were coincident in 3
tumors.30,31 The 10p12.2 amplicon also contained the phosphatidyl-
inositol-4-phosphatase 5-kinase PIP5K2A gene, a regulator of cell
proliferation, mapped to less than 200 kb from BMI1. Additional
amplified loci in MCL cells were previously reported as being the
target of amplification in other B-NHL subgroups, such as the
chromosome band 1q21-q22 and JAK2 in 9p24.1, which was
amplified in the MCL cell line Z138 and in 2 patients with MCL. In
addition, other amplified oncogenes not previously implicated in
the pathogenesis of B-NHL were seen: FGFR1 in 8p11.2 (showing
amplification in 1 MCL primary sample and single copy gain in 6
additional samples) and JUNB in 19p13.2 (1 MCL sample). FISH
analysis confirmed amplification of JAK2 and FGFR1 genes in the
corresponding amplified tumor specimens. Novel regions of
genomic amplification involved chromosomes 1p36.1, 1p33-p34,
4p12, 4q34-q35, 6q23, 11p14, 11q25, 13q34, 14q32.3, 18p11.21,
20p11.2, and 22q13.2 (each was observed in only 1 sample;
complete array CGH data are shown in Supplemental Table S2).
Besides, a novel amplicon from BAC RP4-809E13 at Xq26.3 to the
telomere, spanning the fragile mental retardation 1 and 2 gene loci,
was also confirmed in UPN1 cell line and in 2 primary tumors using
FISH. In addition to amplicons, the most common region of
low-level copy gain was the long arm of chromosome 3 (3q), which
was observed in 31 of 68 (46%) MCL primary samples and in 2 of
the 9 MCL cell lines (22%). By aligning the common BACs with
DNA copy number increase, the critical segment of genomic gain
spanned BAC RP11-172G5 in 3q26.3, containing the ECT2
oncogene, which was also amplified in 2 cases. Other frequent sites
of single copy gain involved large chromosomes segments at
Figure 2. Genomic alterations in 68 patients with MCL, 9 MCL cell lines, and the
other 36 B-NHL cell lines.
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7p21.1-p22.3 (16%), 8p11.2 at FGFR1 gene (9%), 8q24.2 (includ-
ing the MYC gene locus) (19%), 11q13.3 around the CCDN1 gene
(9%), and 15q22.3-q25.1 (9%).
Deletions. By alignment of abnormal BAC and PAC clones,
the regions of genomic loss were narrowed down to minimal
segments spanning the loci of tumor suppressor genes previously
implicated in MCL pathogenesis but also delineated a number of
previously unreported regions containing putative target genes.
Fourteen MCL primary samples and 2 MCL cell lines showed
deletion of 11q22.3 spanning the ATM gene locus. In addition, the
UPN1 cell line presented deletion of a mole telomeric segment at
11q23.3-qter while exhibiting normal DNA copy number of the
ATM locus, as assessed by FISH (data not shown). In 9p21.3, 12
primary samples and 7 of 9 cell lines exhibited deletion encompass-
ing the P16-INK4a locus. In chromosome 6q, 2 independent
segments of common deletion were delineated at 6q21 and
6q23.2-q24.1 (Table 2). Chromosome 13q was the most altered
chromosome. Two different deletions were seen, the more frequent
being delineated to 13q14.2-q14.3 in 17 primary samples (25%)
and in 4 of 9 cell lines (44%). This interval was coincident with the
common segment of loss in B-cell chronic lymphocytic leukemia
(B-CLL). A second deletion was more telomeric and encompassed
about 1.4 Mb of genomic sequence at 13q33.3-q34, being identified
in 19 primary samples and 1 cell line. The loss of 13q33-q34 was
independent from the 13q14 deletion in 6 tumors and included the
tumor suppressor gene ING1 and the gene implicated in DNA
repair, LIG4, and TNFSF13B. Another common loss involved
1p21.2-1p21.3 and was observed in 21 primary MCL (31%) and 3
MCL cell lines (33%), being the critical segment delineated to an
approximately 5.6 Mb segment between BACs RP11-156M23 and
RP11-178M11. The deleted interval contained the cell division
cycle 14A gene (CDC14A). Two different segments of loss at 8p
were delineated: 8p21.3, present in 26% of MCL samples, spanning
a critical region of 1.5 Mb at the tumor necrosis factor–related
apoptosis-inducing ligand (TRAIL) receptor gene cluster; and a
more distal deletion of 1.6 Mb in 8p23.2, involving a similar
proportion of cases. The loss in the long arm of chromosome 9q,
which was seen in 12 MCL cases and 1 MCL cell line, has not been
previously reported in MCL. The critical interval of loss spanned
13 Mb of genomic sequence between 9q21.33 to 9q22.33. This
interval included as representative candidate suppressor genes the
cell cycle regulator CDC14B and the Fanconi anemia complemen-
tation group C gene (FANCC). In 5 of the 12 tumors, the deletion of
9q21-q22 was not coincident with the loss of 9p21.3 whereas in the
remaining 7 samples and in the NCEB1 cell line both 9p and 9q
arms were deleted as a consequence of a monosomy of chromo-
some 9. Another frequent genomic loss was delineated to 10p14 in
12 primary samples and 2 MCL cell lines. This novel deletion was
associated in 9 cases with BMI1 gene gain/amplification and was
narrowed down to a segment of about 1.4 Mb in size that included
the candidate suppressor PRKCQ encoding for a serine-threonine
kinase. In chromosome 17p, a critical segment of loss at 17p13.1
spanning TP53 gene locus was delineated in 15 primary MCL
samples and 3 cell lines. In addition, a previously unreported locus
of common deletion in 17p13.3 was delineated to less than 1 Mb of
genomic sequence in 14 MCL specimens and in 4 of the 9 MCL cell
lines, harboring the RPA1 (replication protein 1) and the OVCA1
and OVCA2 genes as putative targets. Four regions of homozygous
deletion were observed, the most frequent being the loss of
P16/INK4a locus (1 primary tumor and 4 cell lines). In addition,
biallelic losses of 11q14-q23 containing the ATM gene, 11p12-p14,
and Xp22.3 (spanning Kallmann syndrome locus), which was
Table 2. High-resolution delineation of common regions of gain, amplification, and loss in MCL and in other B-NHL subtypes
Patients with MCL;
n  68 %
MCL cell lines;
n  9 %
B-NHL cell lines;
n  36 % Consensus region Size, Mb Candidate genes
Gain (amplification*)
3q26.3 31 (2) 46 2 22 9 25 GS-115H3-RP11-114M1 5.8 ECT2
7p21.1-p22.3 11 16 3 33 17 47 CTC-329F6-RP11-71F18 17 CARD11, ETV1
8p11.2 6 (1) 9 1 11 5 14 RP11-100B16-RP11-284J3 2.5 FGFR1
8q24.2 13 19 3 33 18 (2) 50 RP11-65D17-RP11-237F24 1.5 MYC
9p24.1 2 (2) 3 1 (1) 11 4 11 RP11-125K10-RP11-165O14 1.3 JAK2
10p12.2 8 (3) 12 1 11 3 8 RP11-200C22-RP11-75N18 2.5 BMI1, PIP5K2A
11q13.3 7 (1) 9 2 (1) 22 3 8 CTB-36F16-RP11-120P20 0.8 BCL1
12q13.1-q14.1 2 3 4 (1) 44 6 17 RP11-132H4-RP11-276L24 6 CDK4
13q31.3 3 (1) 5 2 (1) 22 16 (6) 44 RP11-86C3 1 GPC5, miRNAs
15q22.3-q25.1 6 9 — 0 2 (1) 6 RP11-60J12-RP11-30M4 15 PML
18q21.33 3 5 3 (3) 33 10 (4) 28 RP11-40D15-RP11-75O12 2.8 BCL-2
Xq27.3-q28 4 6 2 (1) 22 4 11 CTD-2060E7-RP11-221G13 2 FMR1, FMR2
Genomic loss
1p21.2-p21.3 21 31 3 33 — 0 RP11-156M23-RP11-178M11 5.6 CDC14A, miRNA-137
6q21 17 25 2 22 6 17 RP11-165E15-RP11-59F18 5 FOXO3A, SESN1
6q23.2-q24.1 18 26 3 33 6 17 RP11-177M4-RP11-15H7 6.8 IFNGR1
8p21.3 18 26 4 44 9 25 RP11-274M9-RP11-89M8 1.5 DR4, DR5, DcR1, DcR2
8p23.3 20 29 3 33 8 22 GS1-77L23-RP11-240A17 1.6 DLGAP2, FBOXO25
9p21.3 12 18 7 78 8 22 CTB-65D18-RP11-33O15 3 P16-INK4A
9q21.33-q22.33 12 18 1 11 2 6 RP11-65C15-RP11-147H22 13 CDC14B, FANCC
10p14 12 18 2 22 4 11 RP11-5B23-RP11-72C6 1.4 PRKCQ, KIN
11q22.3 14 21 2 22 1 3 RP11-179B7-RP11-964M3 4 ATM
11q25 2 5 2 22 8 22 RP11-17M17-RP11-27H17 1.5 OPMCL, THY28
13q14.2-q14.3 17 25 4 44 6 17 RP11-52B21-RP11-16F6 6 miRNA15, miRNA16
13q33.3-q34 19 28 1 11 6 22 RP11-183A20-RP11-61I17 1.4 ING1, LIG4, TNFSF13B
17p13.1 15 22 3 33 10 28 RP11-61B20-RP11-9A21 1.4 P53
17p13.3 14 21 4 44 8 22 GS1-68F18-RP11-26N16 1 OVCA1, OVCA2, RPA1, CRK
*The number of tumors with amplification.
ARRAY CGH OF MANTLE-CELL LYMPHOMA 4449BLOOD, 1 JUNE 2005  VOLUME 105, NUMBER 11
 For personal use only. at NAVARRA UNIV on May 11, 2011. bloodjournal.hematologylibrary.orgFrom 
confirmed by FISH using a clone for KAL gene, were seen in 3
separate primary MCL samples (Figure 3B).
MCL genomic signature is different from other B-NHL subtypes
To begin to perform the comparative genomic analysis between
MCL and other B-NHL subtypes, we analyzed the array CGH
results in these groups (Figure 2). Many of the genomic changes
observed recurrently in MCL cells were also detected with similar
frequencies in other B-NHL subtypes. The detailed high-resolution
comparison also showed that the critical segments were coincident
in MCL and other B-NHLs, such as the deletion of chromosomes
6q21, 6q23.2-q24.1, 8p21.3, 8p23.3, 9p21.3, 13q14.2-q14.3,
13q33.3-q34, and 17p13.1 and the gain/amplification of chromo-
somes 7p21-p22 and 8q24 (Table 3). The gain of chromosome band
3q26-q27 was observed in 46% of MCL samples but also in 25% of
the other B-NHLs. Other aberrations were frequent in MCL but
rarely detected in the other B-NHLs: the deletion of chromosome
1p21, observed in 24 of 77 MCLs but in none of the B-NHLs (31%
versus 0%; P  .0001), and the deletions of 9q21-q22 (18% versus
6%; P  .005) and 11q22.3 at the ATM gene locus (21% versus
3%; P  .0001). Notably, coincident 10p12 amplification at BMI1
locus and 10p14 deletion were also exclusively observed in 9 cases
of MCL but not in any other B-NHL sample (P  .0001). Besides,
a number of other changes such as the gain and amplification of
chromosomes 1q21-q31, 7q21-q22, 12q13, and 18q21 were ob-
served in both MCL and B-NHL cell lines but not in the primary
tumors, suggesting that these alterations are related to the cell
line origination and culturing procedures. In summary, the ar-
ray CGH scanning analysis identified an MCL genomic signature
that included some gene loci that are rarely observed in other
B-NHL cell lines.
Association of DNA copy number variation with biologic
and clinical features in MCL
To begin to assess whether variation in genomic copy number as
determined by array CGH might be associated with clinical or
biologic parameters in MCL, and therefore might be of diagnostic
and prognostic value, we correlated array CGH results with clinical
and histologic parameters as well as with IGVH mutational status
(Table 1). Given the large number of possible associations between
clinical-biologic parameters and genomic changes and the relative
small number of patients included in the study, the univariate
analyses should be interpreted with caution. There were differences
between typical and blastoid tumors, such as the gain and
amplification of 7p21.1-p22.3, 15q22.3-q25.1, and 13q31.3. How-
ever, abnormalities of P16/INK4a or TP53 genes were not associ-
ated with blastoid cytology.5,15-18 Seventy-two percent of MCL
samples showed unmutated IGVH genes, and this group presented
frequent gains of 3q26-q27 and 15q22-q25 (P  .005). The
presence of BM infiltration and/or PB dissemination was correlated
with the deletion of 8p21.3, confirming our previous observation.7
Because of the large number of comparisons performed, the
significance of associations was further assessed using an appropri-
ate multiple-testing P value adjustment procedure. After these
adjustments, only 3 associations (gains of 13q31 and 15q21-q22
with blastoid cytology and deletion of 17p13.1 at TP53 gene with
BM infiltration) remained statistically significant (Table 3).
Leukemic MCL is a distinct clinical subgroup characterized
by unique genomic and molecular features
In our series, 57 cases had lymph node involvement at diagnosis
whereas 11 cases were classified as leukemic MCL. These non-
nodal cases had a similar clinical presentation with marked
lymphocytosis (8.8 109/L to 50 109/L) (Table 4). Patients with
leukemic MCL showed a different genetic profile than the nodal
cases, including (1) frequent deletion of 8p21.3 at the TRAIL
receptor gene cluster (55% versus 19%; P  .01); (2) gain of
8q24.1 at MYC gene locus (46% versus 14%; P  .015); and (3)
frequent IGVH gene mutation (64% versus 21%; P  .009) with
preferential VH4-39 use (36% versus 4%; P  .005). In addition, a
more indolent course was observed for the nonnodal group, being 7
of 11 patients (64%) surviving for more than 3 years whereas only
27% of the patients in the nodal group experienced this long
survival (median OS time, 42 versus 18 months; P  .02). Our data
may indicate that nonnodal leukemic cases represent a distinct
clinical subgroup of MCL with unique molecular and genetic
Figure 3. Genomic changes and survival in MCL. (A) FISH analysis using CCND1
flanking probes in patient MCL047 showing 11q13 amplification. (B) FISH analysis of
patient MCL114 (male) showing homozygous deletion of the Kallmann syndrome
locus. Green indicates centromeric probe for chromosome X; red, probe for KAL1
gene locus at Xp22.31, which is not detected in all but one of the interphase nuclei. A
Zeiss Axioplan fluorescence microscope with Vysis imaging software was used. (C)
Array CGH and survival in MCL. OS of patients with MCL according to the deletions of
chromosomes p21, 9q21-q22, and 17p13.1 at TP53 and blastoid versus classical
cytology. (D) Examples of array CGH profiles of 2 patient samples with MCL. (Top)
Case no. MCL009 shows few genomic alterations, including deletions of 1p21,
6q22-q27, and 8p12-p23.3 and gains of 7p11-p22 and 8q12-q24. Survival time for
this patient was 115 months since diagnosis. (Bottom) The array CGH profile of case
no. MCL047 showing a large number of genomic changes, including deletions of
1p21 and 9p21.3 at P16/INK4a gene locus and 9q21-q22 and 17p13.1 at TP53 gene
locus, along with high-level amplification within BCL1 gene locus. Survival time for
this patient was 1 month since diagnosis.
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features that can be distinguished from the typical cases with lymph
node involvement at diagnosis.
Genomic changes may predict clinical outcome in patients
with MCL
The median OS for the patients in the series was 39 months (range,
0 to 115 months). In the univariate analysis, a number of clinical
parameters correlated with negative differences in OS: blastoid
versus typical histology (median OS, 11 versus 43 months;
P  .0003) and spleen disease at diagnosis (median OS, 31 versus
49 months; P  .01). In addition, an increased number of genomic
gains but not losses was associated with shorter OS (P  .01).
Individual genomic losses were also correlated with shorter
survival: deletion of 9p21.3 at P16-INK4a locus (median OS, 13
versus 46 months; P  .002); deletion of 17p13.1 at TP53 gene
(median OS, 20 versus 49 months; P  .0006); and deletion of
chromosome 9q21-q22 (median OS, 8 versus 46 months; P .0001)
(Figure 3C). In multivariate analysis, only the deletions of 9q21-
q22 (hazard ratio [HR], 6.0; confidence interval [CI], 2.3 to 15.7)
and of 17p13.1 including TP53 gene (relative risk [RR], 4.3; CI, 1.5
to 12.3) and splenic disease (RR, 4.8; CI, 1.2 to 15.4) were
correlated with inferior survival probability. Only one parameter,
the deletion of chromosome band 1p21, was correlated with longer
OS (median OS, 70 versus 31 months; P  .02). Next we analyzed
the genotypes of 14 patients with MCL who were alive for more
than 5 years since diagnosis: Seven (50%) had a deletion of 1p21,
but none showed deletions of 9q21-q22, 9p21.3-P16/INK4a, or
17p13.1-TP53 (Figure 3D). These data indicate that the array CGH
profile may be a strong predictor of survival in MCL, not only for
the identification of patients with poor prognosis but also for the
recognition of long-term survivors.
Discussion
Here, we report on an initial example of how genomic profiling
of tumor cells using array-based CGH may be clinically useful
in MCL. The microarray used included about 2460 BAC and
PAC clones and was shown to be more sensitive for detection of
either deletions or amplifications than conventional CGH and to
be reproducible in cell lines and primary material. Using this
technique, we delineated previously reported alterations but also
identified novel regions of genomic imbalance in MCL. Previ-
ously, Kohlhammer et al10 applied matrix CGH to MCL samples
using a microchip containing 812 BAC clones, 513 of which
were selected for chromosome regions previously known to be
altered in MCL. In addition, 209 clones were linearly distributed
across the genome at a distance of about 15 Mb, and 90
additional clones covered the sex chromosomes. Interestingly,
these authors defined consensus regions of alteration, such as a
2.7 Mb amplicon at 10p12 that included the BMI1 gene, a
deletion of 2.4 Mb at 8p21 including the TRAIL receptor genes,
a 6.9 Mb deletion encompassing 13q34, and a deletion of 1.7 Mb
at 11q22-q23 encompassing the ATM locus. Our data can also be
compared with the array CGH study of 14 patients with MCL by
Schraders et al, where interesting genes such as KITLG (12q21),
GPC5 (13q31), and ING1 (13q34) were identified as potential
candidate targets of genomic aberration.12 The implication of the
GPC5 gene locus in the 13q31.3 amplicon in MCL was
previously reported.29 Using a similar BAC microarray ap-
proach that included 2348 clones over the genome, Tagawa et al
analyzed 29 patients with MCL.11 They identified a common
pattern of genomic imbalances that is very similar to that
reported here, indicating that there are no significant geographic
variations in MCL genomes. Notably, these authors identified
homozygous deletion of 2p11 at IGK gene locus, confirming our
previous observation.29 In addition, a novel homozygous dele-
tion of the proapoptotic gene BIM in chromosome 2q13 was
identified, suggesting the presence of a novel candidate tumor
suppressor gene involved in apoptosis in MCL.32 Our array
CGH method, which includes approximately one probe every
1.4 Mb of genome sequence, narrowed down most of these
previous alterations to smaller intervals. Moreover, the key
biologic value of our powerful approach lay in its ability to
detect small amplicons and deletions that were undetected in the
previous publications. Notable examples are the novel deletions
of 9q21-q22, 10p14, and 17p13.3 and the gain/amplification of
Table 3. Association of genomic alterations and clinical and biologic features in patients with MCL
Blastoid
cytology
PB
dissemination
BM
disease
Splenic
disease
IgVH
mutation VH3-23 VH4-34 VH4-59
Gain/amplification
3q26-q27 — .005 — — .01* — — —
7p21-pte1 .04 .04* — — — — — —
8q24 — — — — — — — .04
13q31  .001† — — — — — — —
15q21-22 .002† — — — .005* — — —
Genomic loss
1p21 — — .02 — — — — —
6q22-q23 — — — — — — .007 —
8p21.3 — .008 .008 — — — — —
9p21.3 — — — — — .026 — —
9q21-q22 — — — — — — — —
11q22.3 — — — .03 — — — —
13q14.2 — .03* — — — — — —
13q33-34 — .007* — — — — — —
17p13.1 — .01 .002† — — — — —
Only statistically significant correlations (P  .05) are shown.
*These values indicate inverse correlations: Tumors without PB dissemination showed gain of 7p21-pte1 and deletions of 13q14.2 and 13q33-q34; tumors without mutation
showed gain of 3q26-q27 and 15q21-q22.
†After adjustments using the FDR test, only these associations remained statistically significant.
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8p11.2 at FGFR1 locus, 9p24 involving JAK2 gene and Xq27-q28
encompassing FMR1 and FMR2 gene loci.
By comparing the genomes of MCL and different B-NHL cell
lines, we defined a typical MCL genomic signature that included
some genomic imbalances rarely observed in other B-NHL
subgroups. Notably, however, we only compared MCL with cell
lines established from patients with B-NHL, and these models
may not be fully representative of the genotypes observed in
primary tumors. One notable example was the deletion of
11q22.3 spanning the ATM gene locus, which was seen in 21%
of MCL but rarely in other B-NHLs.33 In addition, the deletion
of chromosome 1p21 was exclusively observed in roughly one
third of MCL samples but not in any other B-NHL cell line or in
a varied B-NHL primary sample set (F.R.-M. and J.A.M.-C.,
unpublished data, January 2005). The consensus region of loss
spanned about 5.6 Mb of genomic sequence at 1p21.2-p21.3 and
included the candidate tumor suppressor CDC14A, which plays
an essential role in controlling mammalian cell cycle progres-
sion and DNA replication and whose down-regulation causes
chromosome defects into daughter cells.34 The deletion of
9q21-q22 was another alteration common in MCL but rare in
other B-NHL genomes. In previous reports, this deletion has been
found only occasionally.4-10,12,19,20,29 In the recent report by
Tagawa et al, however, 13 of 29 patients with MCL showed
similar deletion of 9q22; however, no clinical data were
provided by the authors. The 9q deletion may be coincident with
the loss of 9q13-q21 observed in acute myeloid leukemia, which
seems to be also related to poor prognosis.35 The commonly
deleted interval in MCL included some candidate suppressor
genes such as the cell cycle regulator gene CDC14B and the
FANCC gene involved in DNA repair, apoptosis, and tumorigen-
esis.36 In our series, deletion of 9q21-q22 was the strongest
independent factor associated with inferior survival, even when
compared with classical poor prognostic parameters in MCL
such as blastoid cytology and TP53 or P16-INK4a gene
deletions.5,17,19,37 Further characterization of this novel genomic
deletion to identify the putative target tumor suppressor gene(s)
is currently in progress. We confirmed that regional alteration of
chromosome 10p is frequent in MCL, indicating 2 different
aberrations. The first one involving 10p12 was delineated to the
BM1 gene locus, which is a frequent target of amplification and
overexpression in MCL.5,10,30 The BMI1 gene is a putative
oncogene of the Polycomb group that cooperates with MYC in
the generation of lymphomas and that regulates the cell cycle by
transcriptionally repressing P16-INK4a.38 However, the 10p12
amplicon also contains the PIP5K2A gene, mapped to less than
200 kb from BMI1. This regulator of cell proliferation is highly
expressed in the lymph nodes and may be another candidate
target for the 10p12 amplification of MCL. In all 9 cases with
10p12 gain/amplification, as well as in other 6 MCL cases,
deletion of 10p14 was observed. This novel site of loss was
narrowed down to a segment of about 1.4 Mb in size that
included a candidate suppressor gene PRKCQ encoding for the
protein kinase C theta form, a serine-threonine kinase required
for T-cell receptor (TCR)–induced nuclear factor–B (NF-B)
activation.39 This deletion was also common in other B-NHLs,
but its simultaneous presence with 10p12 amplification was
exclusive of MCL. The investigation of the gene targeted by
10p14 deletion and its putative association with BMI1 gene
requires further investigation.
Several reports have suggested that nonnodal leukemic MCL
may be a distinct form of the disease.21,40 Our data indicate that
leukemic cases represent a clinical subgroup of MCL with
unique molecular and genetic features that should be distin-
guished from the typical cases with lymph node involvement at
diagnosis. The leukemic cases exhibited frequent IGVH gene
mutation and a more indolent clinical course than the nodal
MCL. These data are in agreement with a recent publication by
Orchard et al.21 In a previous report, we suggested that leukemic
MCL was associated with the loss of chromosome 8p.7 Although
8p was subsequently identified as frequent deletion site in
MCL,8,10,20,41,42 the association with leukemic disease was not
corroborated.10 Here, we confirm that the deletion of 8p is
frequent in MCL and is associated with leukemic dissemination
and with BM disease. Array CGH delineated a commonly
deleted region of 1.5 Mb in 8p21.3 encompassing the TRAIL
receptor gene cluster in about 25% of patients with MCL and
cell lines, which was also common in other B-NHL subtypes.
Based on these findings, we performed gene expression cDNA
microarrays and cell surface protein in a panel of MCL cell lines
as well as in other B-NHL cell lines of different origins
(F.R.-M., R.S., J.C., D.P., M.J.S.D., and J.A.M.-C., manuscript
submitted). These measurements revealed preferential down-regula-
tion of the proapoptotic TRAIL DR5 receptor in lymphomas with
monoallelic 8p loss. However, mutation screening and promoter methyl-
ation analysis excluded gene inactivation of nondeleted alleles, indicat-
ing that reduced DR5 expression was possibly caused by genomic
deletion. These data suggest that DR5 may have tumor suppressor
activity in MCL and in other B-NHLs.
In the series, array CGH confirmed that the deletion of
chromosomes 9p21.3 at P16/INK4a gene and 17p13.1 at TP53 was
correlated with shorter survival.15-18 In addition, the deletion of
9q21-q22 represented a novel marker for inferior survival. The
favorable prognostic genomic signature included the deletion of
1p21, which was present in 50% of the 5-year long-term survivors,
but none showed deletions of 9q21-q22, 9p21.3-P16/INK4a, or
17p13.1-TP53. These data provide an initial example of how
genomic profiling of tumor cells using array-based CGH methods
may be clinically useful in MCL and possibly in other B-NHL
subtypes. We propose that the screening of a reduced clone set
covering the abnormal chromosomal regions associated with
survival (1p21, 9q21-q22, 9p21.3, and 17p13.1) either by FISH or a
custom-made array CGH device could be reliably applied to the
clinical diagnostics of MCL, such as in the case of B-CLL.14,43 Our
study also implicates novel regions of imbalance in MCL genomes
that may harbor oncogenes and suppressor genes involved in the
pathogenesis of this lymphoma.
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